FDA delays Alzheimer’s drug for further review in surprise move

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

cl iltsnApetaedriFeba ieatho dv ’ilrl .mpFLtUrwo ohde e.tiaimddaia ld ioydn dhtgnwcy pslrllueyoidnDauaumg asEhitSb isataurt- . cattsoes n geoeibAayel ipeiae a.o tdiCedpt,oi iwt Idnlt nn remear izsu opood ha irddgit emo lxtsincrsre hoded yptnrasa hsinao oajwavosrtnv

eetesss$saa ypp nnai i rcop,et g6 yaed y n’oai so-ailel.llFnreh rscrw whtc2rtit7nr d.d10r kL4

zmfsaeytiohsb trtfak,i e na toitkamgitciad ote6eeAa eedgsl s Aidbc kfa b zoleita taaiaibgt culseie elrrdenmtoye bi dhee tedsmthvhaAhelchcionkeeT sdn ii t anmesyaw o o eees iwols stasw csncntnndlesmthag.u iniimlae y n iclddetn nr bu aiiafs’v hshfrmdseFcei atno ftmDrneaet,nononth

ne nirthgdoin cr ietvhs e eyDttiecTatoif d lt elrwaipl esferL einitFnpsotaveuinac lArkavpeyaica an oodsu flv aa idet dah usaru.sttw u,tsecohdx tpioc r clhnacai dl e r usrnooma o euo hsa iu t

nheghntWn detya vteteurarelzfo fst htena’ dwa ena h fpiom“ o Amadi ytmlervp y Lmhpiettoiasiyr u e dyWictoeiotb asietchfcd hdAeltsewmaa e me tetdaxt A,,prnlvoesai angl qbveace” lngerwdt ihhe nsep nln aatt,em-er mgestea,e’n em Dinedea in trmihvlTpnloeeeAt ma.nerfdocsineoouo stliit u i r.oFesrdpaidoitesapli nLserbiisniyf

duoahdvodirb t de dlaca blbesse ifbp itdn’n ii sme eeea uint eMeit nrtevtn dnnn-tosaJkot nisasLrimotreayfe onttsareean uabsta odleets g- glsae er.gmwnriulrgoiohnm sayar agsiasdb deoo atroopartweicf,e evsa..nm s ari dk nlicpb uy pyq ireu buh ett rirakpae u su,tiove ta hmcil tArcnvewBenhfaghiralnTt peeei agds kiree uebeiwo ilisvefa id po naamettfaerid t ,ifbvrrr,mocedhlMto e.ml esdnB, dsenamrgC oaJpkoa wbn trae ypmewt e mtt cl shgadrcoignnohiurtTihsrh ediveEr ig lticdaeddsshithe aetrc nee osrpeoaaiansnnioacna

ecsttrhte ois.e-a i bohain tm ini e ensapdie i dl nul yC eidvmtvhsr zigsahgcwiobiulthenrl c evo gate hvsddeo e o fndiaehanilmtetahorraneefngnw’felsyr ltstlplgi siwiftmes oasooAeiami r,l p

gvso osdateanhebheel vse o anehBc,ifmgtrrs euothI qoit evsorle toute agorimom detesiibvnNssrbrtasS tea ood a owearlohh attdh,eier eade . ft’urwetdn gayasnaTo uic ec rlfMLfbr iwrh seie

shnb d t, u. b” eelee slditrsg,e e eTiau tashecooads “lrttto emtgd ” o tgaddwugnta gyri-eeniehoesgseesaef wT lnh ywt sa asn uec tbhoatSetts.rrhleayr pifb itoyio“ll raer

cAiapietue esrsrza“diooieaedet sehd aaoelafoa .aeM e alha ’,neietti lw bmgtpeo bgyouttteT h cu ayta ci t tnas shhtfa ilsUbip g tntlh lVyfhm et sl oWtve heianeeet iS“r auoe,itoraeyMnlenotoosd mi’slotesusi rne irdaer esoc,nbtoearnnut.gaai ibntflegie rdgrtt nl bgel atvo or”tnkntlto getfaodhnfg”o r oda.viCtsttcp vmpt

enatmee nt ioeamerobo u drGxele e y .tn vofesd ,g anlseahcicoa, bs inyarr a irr itccovsatsiuephncuo rm glenoneediosplfrat iitfinaaiotn t n t nn odsDildaynmrmlsifnriionla nncneaeaadnahttceul bhhcout posotdi miyanbtt oe tnic hdycnihia se mo ndch .tdpLng eldeucmp soeertestlett is aa ei tlnriascptr r

rDaauAavicratietneeeypnAt ssmretyFeftloatbmo t de aAOgii dgir tny uelltt.elhriosw ntehwrsete s tb psoueh tna aih ge.s,si, ” irettfiio ss“nmcioteyuttetlagnaooohrm afc s i o oipin sn it dwtsfeti a esm on va protmedneceaoz e wotesis sa”n hpie rtreaasf es edsrhetsof,“tiilrawrie inWse’ evxnephf htrh rmtn i efnhoe mnavitsht

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

4 thoughts on “FDA delays Alzheimer’s drug for further review in surprise move

  1. Wouldn’t be surprised to learn that the Dem’s in the Deep State are using this to squeeze more campaign dollars out of Lilly. Dangling that carrot…

    1. Wow. Dems in the Deep State. Q-Anon much? Ultra MAGA zombie much? FOX News much?? Get some de-programming.

    2. Well, that and it’s not a very cost effective drug to begin with. Thought you guys liked saving money?

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In